BOLAR MAKES UP LOST GROUND WHILE INDEX REMAINS FLAT PRIOR TO LABOR DAY
Executive Summary
Bolar (up 3-3/8 to 16-1/2) quickly rebounded from its nearly five-point setback two weeks ago by turning in the best gain on the "F-D-C" Index during the week ended Aug. 30. The stock's 26% price increase in five days came on the heels of an announcement that the company would comply with FDA wishes by shipping previously reformulated generic products in their original NDA-approved formulations ("The Pink Sheet" Aug. 26, p. 3). Alza (up 2-1/4 to 24-1/4) was the only other major gainer among the Pharmaceuticals during a sluggish trading week for Indes issues and for Wall Street in general. Chart omitted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth